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ABSTRACT
Background. Lung adenocarcinoma with micropapillary
and solid predominant subtypes was reported to be asso-
ciated with poor prognosis; however, whether minor
components (non-predominant) of micropapillary and solid
subtypes predict poor prognosis remains unknown. In this
study, we investigated the predictive and prognostic value
of lymph node metastasis of minor micropapillary and
solid components.
Methods. Specimens of resected tumors of 1244 patients
were reclassified to determine the predominant subtype and
minor components ([5 %, but not predominant). Of these
specimens, 105 contained a micropapillary component and
210 contained a solid component. The correlation between
each subtype and lymph node metastasis was analyzed, and
survival analyses were used to determine the association
between each subtype and patient survival.
Results. Adenocarcinomas harboring micropapillary and/
or solid components held higher rates of metastatic lymph
node stations (25.2 % vs. 15.6 %, p = 0.002; and 24.0 % vs.
14.9 %, p\0.001, respectively) and lymph nodes (17.3 %
vs. 10.1 %, p = 0.004; and 15.5 % vs. 9.7 %, p = 0.001,
respectively). Patients with micropapillary and solid com-
ponents in their tumors showed a shorter median
recurrence-free survival (15.8 vs. 62.8 months, p\ 0.001;
and 20.8 months vs. not reached, p\ 0.001) and overall
survival (47.0 months vs. not reached, p\0.001; and 69.0
months vs. not reached, p\ 0.001).
Conclusions. Minor components of micropapillary and/or
solid subtypes of lung adenocarcinoma are correlated with
lymph node metastasis and poor prognosis. Thus, it is
beneficial to focus not only on predominant subtypes but
also minor components to predict prognoses and make
therapeutic strategies more comprehensively.
Adenocarcinoma has long been an independent histo-
logical class of lung cancer and has been broadly studied for
therapeutic efficacy and toxicities.1–5 In 2011, a new clas-
sification system of subtypes of lung adenocarcinoma was
recommended by the International Association for the Study
of Lung Cancer (IASLC), American Thoracic Society
(ATS), and European Respiratory Society (ERS) to further
study and advance the field.6 Since then, a number of
investigations have provided evidence for the relationship
between different subtypes and treatment outcomes.7–11
Several studies have reported that micropapillary- and
solid-predominant subtypes of lung adenocarcinoma were
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associated with poor prognoses;12–16 however, lung ade-
nocarcinomas usually contain complex mixtures of
different subtypes.17 Whether minor components of each
subtype are associated with lymph node metastasis and
poor prognosis still remains unknown and needs further
clarification.
In this study, we comprehensively analyzed 1244 con-
secutive patients who were diagnosed with stage I–IV
invasive lung adenocarcinoma and who underwent surgical
resection between August 2006 and May 2013. Our aim
was to provide clinical evidence for the predictive and




Overall, 1244 consecutive patients who were diagnosed
with invasive lung adenocarcinoma and who underwent
surgical resection between August 2006 and May 2013
were included in this study. R0 resection was achieved in
1240 of the 1244 patients. Patients with no or insufficient
archived tumor specimens were excluded, and no patient
underwent neoadjuvant therapy. To ensure an accurate
assessment, tumors were reclassified by three pathologists
(XS, LS, and YL) and categorized into the following
subtypes: lepidic (L), acinar (A), papillary (P), micropap-
illary (M), and solid (S) predominant subtypes, as well as
invasive mucinous adenocarcinoma (IMA), according to
the newly announced IASLC/ATS/ERS lung adenocarci-
noma classification system.6 Each of the 1244 slides was
reviewed by these three pathologists separately. Discordant
results were reconsidered together by the three pathologists
until a consensus was reached. Specimens that did not
belong to any one of these categories were marked as
‘others’. For those specimens that were mixed by more
than one subtype, the subtype that occupied most of the
tumor (even if \50 %) was defined as the predominant
subtype, and subtype(s) that occupied no less than 5 % but
were not predominant were defined as minor components.
We put them in a sequence from the largest to the smallest
amount.
This study was approved by the Committee for Ethical
Review of Research (Fudan University Shanghai Cancer
Center IRB# 090977-1).
Statistical Analysis
Clinical and pathological characteristics, such as sex,
age, smoking status, lymphovascular invasion status, tumor
location, and nodal status (N0, N1, or N2), together with
predominant subtypes and minor components, were ana-
lyzed to determine the correlation with lymph node
metastasis. p values, hazard ratios and 95 % confidence
intervals (CI) were calculated using Pearson’s Chi square
test or Fisher’s exact test, and the two-tailed significance
level was set at 0.05. Metastatic rates of lymph node sta-
tions and lymph nodes of each predominant subtype and
minor component were calculated to evaluate the correla-
tion between lymph node metastasis and each subtype. p
values were calculated using Student’s t test. Moreover,
Kaplan–Meier survival curves were used to compare
patients’ recurrence-free survival (RFS) and overall sur-
vival (OS). Finally, a multivariate Cox model adjusted for
sex, age, smoking status, lymphovascular invasion status,
tumor location, and nodal status (N0, N1, or N2) was used
to determine the odds ratio (OR) and 95 % CI for each
minor component. All statistical analyses were performed
using SPSS version 20.0 (IBM Corporation, Armonk, NY,
USA).
RESULTS
For the 1244 patients with pathologically validated lung
adenocarcinoma included in this study, a reclassification by
three pathologists manifested that there were 158 lepidic-
predominant, 598 acinar-predominant, 170 papillary-pre-
dominant, 68 micropapillary-predominant, 171 solid-
predominant, and 72 invasive mucinous adenocarcinoma.
Clinical and pathological characteristics are shown in
Table 1. Of the 1244 patients, 109 had a tumor containing a
minor component of lepidic subtype, 196 a minor acinar
component, 178 a minor papillary component, 105 a minor
micropapillary component, 210 a minor solid component,
and 62 had a tumor containing a minor invasive mucinous
component. Patients were aged 60 years (range 22–110),
560 were males and 684 were females (Table 1). The
pathologic stage was 0 in 6 (0.5 %) patients, IA in 517
(41.6 %) patients, IB in 178 (14.3 %) patients, IIA in 120
(9.6 %) patients, IIB in 46 (3.7 %) patients, IIIA in 338
(27.2 %) patients, IIIB in 15 (1.2 %) patients, and IV in 24
(1.9 %) patients.
The Predictive Value of Lymph Node Metastasis
Of the 1244 patients, 789 (63.4 %) had pathologically
validated N0 disease and 455 (36.6 %) had either patho-
logically validated N1 or N2 disease (Table 1). Our data
showed that lymph node metastasis had a correlation with
male sex (p\ 0.001), younger age at initial diagnosis
(p = 0.023), ever-smoker (p\ 0.001), lymphovascular
invasion (p\ 0.001), poor differentiation (p\ 0.001), and
larger tumor size (p\ 0.001). The micropapillary-
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predominant subtype (p = 0.035; HR 1.353; 95 % CI
1.046–1.748) and solid-predominant subtype (p\ 0.001;
HR 1.976; 95 % CI 1.715–2.278) were both associated
with lymph node metastasis, along with the papillary minor
component (p = 0.008; HR 1.297; 95 % CI 1.083–1.553),
micropapillary minor component (p\ 0.001; HR 1.522;
95 % CI 1.252–1.852), and solid minor component
(p\ 0.001; HR 1.513; 95 % CI 1.292–1.773). On the other
TABLE 1 Clinicopathological characteristics of different subtypes of lung adenocarcinoma (n = 1244)
Total N0 (n = 789) N1/N2 (n = 455) p value HR (95 % CI)
Gender
Male 560 (45.0 %) 327 (41.4 %) 233 (51.2 %) 0.001 1.282 (1.108–1.483)
Female 684 (55.0 %) 462 (58.6 %) 222 (48.8 %)
Age
\Average 598 (48.1 %) 360 (45.6 %) 238 (52.3 %) 0.023 1.185 (1.023–1.372)
C Average 646 (51.9 %) 429 (54.4 %) 217 (47.7 %)
Smoking status
Former/current 403 (32.4 %) 225 (28.5 %) 178 (39.1 %) \0.001 1.340 (1.159–1.553)
Never 841 (67.6 %) 564 (71.5 %) 277 (60.9 %)
Tumor locationa
LUL 330 (26.5 %) 193 (24.5 %) 137 (30.1 %) 0.033 0.838 (0.717–0.979)
LLL 200 (16.1 %) 119 (15.1 %) 81 (17.8 %) 0.208 0.885 (0.734–1.066)
RUL 406 (32.6 %) 274 (34.7 %) 132 (29.0 %) 0.038 1.186 (1.006–1.397)
RML 103 (8.3 %) 64 (8.1 %) 39 (8.6 %) 0.777 0.963 (0.743–1.248)
RLL 231 (18.6 %) 150 (19.0 %) 81 (17.8 %) 0.597 1.053 (0.868–1.277)
LVI
Yes 203 (16.3 %) 35 (4.4 %) 168 (36.9 %) \0.001 3.003 (2.674–3.378)
No 1041 (83.7 %) 754 (95.6 %) 287 (63.1 %)
Differentiation
Well 169 (13.6 %) 153 (19.4 %) 16 (3.5 %) \0.001 0.232 (0.145–0.372)
Moderate 714 (57.4 %) 492 (62.4 %) 222 (48.8 %) \0.001 0.707 (0.612–0.818)
Poor 361 (29.0 %) 144 (18.3 %) 217 (47.7 %) \0.001 2.232 (1.946–2.558)
Tumor size (cm)
\ 3 756 (60.8 %) 572 (72.5 %) 184 (40.4 %) \0.001 2.283 (1.965–2.646)
C 3 488 (39.2 %) 217 (27.5 %) 271 (59.6 %)
Predominant subtype
L 158 (12.7 %) 154 (19.5 %) 4 (0.9 %) \0.001 0.061 (0.023–0.161)
A 598 (48.1 %) 211 (46.4 %) 387 (49.0 %) 0.363 0.935 (0.806–1.082)
P 170 (13.7 %) 98 (12.4 %) 72 (15.8 %) 0.092 1.188 (0.979–1.441)
M 68 (5.5 %) 35 (4.4 %) 33 (7.3 %) 0.035 1.353 (1.046–1.748)
S 171 (13.7 %) 62 (7.9 %) 109 (24.0 %) \0.001 1.976 (1.715–2.278)
IMA 72 (5.8 %) 48 (6.1 %) 24 (5.3 %) 0.556 0.907 (0.648–1.267)
Minor components
L 109 (8.8 %) 94 (11.9 %) 15 (3.3 %) \0.001 0.355 (0.221–0.571)
A 196 (15.8 %) 123 (15.6 %) 73 (16.0 %) 0.832 1.021 (0.838–1.247)
P 178 (14.3 %) 97 (12.3 %) 81 (17.8 %) 0.008 1.297 (1.083–1.553)
M 105 (8.4 %) 49 (6.2 %) 56 (12.3 %) \0.001 1.522 (1.252–1.852)
S 210 (16.9 %) 103 (13.1 %) 107 (23.5 %) \0.001 1.513 (1.292–1.773)
IMA 62 (5.0 %) 34 (4.3 %) 28 (6.2 %) 0.150 1.250 (0.941–1.661)
p value, HR, and 95 % CI were calculated using the Chi square test and Fisher’s exact test
HR hazard ratio, CI confidence interval, LUL left upper lobe, LLL left lower lobe, RUL right upper lobe, RML right middle lobe, RLL right lower
lobe, LVI lymphovascular invasion, L lepidic, A acinar, P papillary, M micropapillary, S solid, IMA invasive mucinous adenocarcinoma
a When adding the percentage of this category together, a number more than 100 % may be obtained as some tumors occurred in more than one
lobe
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hand, tumors presenting as well-differentiated (p\ 0.001)
or moderately differentiated (p\ 0.001), lepidic-predomi-
nant subtype (p\ 0.001), and lepidic minor component
(p\ 0.001) showed lower probabilities of having lymph
node metastasis (Table 1).
To further investigate the correlation between different
subtypes and lymph node metastasis, we also recorded the
number of metastatic lymph node stations/lymph nodes and
resected lymph node stations/lymph nodes, and made a
calculation of metastatic rates (Tables 2, 3). Regional
lymph node stations were defined as per the recommen-
dations made by Mountain and Dresler in 1997.18
According to our data, tumors harboring the micropapillary
minor component and solid minor component had higher
metastatic rates of lymph node station (25.2 vs. 15.6 %,
p = 0.002; and 24.0 vs. 14.9 %, p\ 0.001, respectively)
and lymph node (17.3 vs. 10.1 %, p = 0.004; and 15.5 vs.
9.7 %, p = 0.001, respectively). A similar trend was
observed in tumors with micropapillary-predominant and
solid-predominant subtypes (Tables 2, 3). Additionally, we
found that patients with lepidic-predominant or minor
component tumors had a lower probability of experiencing
lymph node metastasis (also shown in Tables 2, 3). Fur-
thermore, we also analyzed the relationship between the
second predominant subtype and lymph node metastasis.
All 606 patients with two or more presenting subtypes were
included (see electronic supplementary Table 1), and this
analysis showed a similar result as previous ones (see
electronic supplementary Tables 2 and 3).
Does Each Subtype Predict a Different Prognosis?
Of the 1244 patients, 288 lacked sufficient follow-up
data; therefore, we included the remaining 956 patients in
subsequent survival analysis. Seventy-eight of the 956
patients had a tumor containing a minor micropapillary
component, and 124 had a tumor containing a minor solid
component, along with 19 micropapillary-predominant
subtypes and 161 solid-predominant subtypes (Fig. 1).
In univariate analysis, patients with tumors containing a
minor component of micropapillary subtype had a signifi-
cantly shorter RFS (p\ 0.001) and OS (p\ 0.001). A
similar observation was made among patients with tumors
containing a minor component of solid subtype, which also
showed a significantly shorter RFS (p\ 0.001) and OS
(p\ 0.001). Meanwhile, patients with tumors of
micropapillary- or solid-predominant subtype also had
significantly worse RFS (p = 0.006 and p\ 0.001,
respectively) and OS (p = 0.007 and p\ 0.001,
respectively).
In a multivariate analysis using the Cox model adjusted
for sex, age, smoking status, lymphovascular invasion
status, tumor location, and nodal status (N0, N1, or N2), we
found that tumors with a minor component of micropap-
illary subtype were correlated with shorter RFS
(p\ 0.001; OR 0.524; 95 % CI 0.388–0.708) and OS
(p = 0.012; OR 0.585; 95 % CI 0.385–0.890) (Table 4).
Tumors with a minor component of solid subtype were also
related to a worse RFS (p = 0.014; OR 0.728; 95 % CI
0.567–0.936) and OS (p = 0.039; OR 0.690; 95 % CI
TABLE 2 Relationship between different subtypes of lung adenocarcinoma and metastatic rate of lymph node station (n = 1244)
Subtype Negative (%)a Minor component (%) p value Predominant (%) p value
L 17.5 5.2 \0.001 8.2 \0.001
A 16.6 15.6 0.650 15.5 0.233
P 15.9 19.5 0.106 20.1 0.081
M 15.6 25.2 0.002 23.8 0.066
S 14.9 24.0 \0.001 28.7 \0.001
IMA 16.2 21.4 0.138 14.7 0.580
Metastatic rate of lymph node station = (number of metastatic lymph node stations/number of totally resected lymph node stations) 9 100 %
L lepidic, A acinar, P papillary, M micropapillary, S solid, IMA invasive mucinous adenocarcinoma
a Percentage of patients with subtype of interest not observed or less than 5 %
TABLE 3 Relationship between different subtypes of lung adeno-








L 11.4 3.1 \0.001 6.3 \0.001
A 10.8 10.1 0.663 9.8 0.176
P 10.5 11.9 0.397 13.5 0.081
M 10.1 17.3 0.004 17.5 0.056
S 9.7 15.5 0.001 18.0 \0.001
IMA 10.6 12.7 0.441 9.7 0.687
Metastatic rate of lymph node = (number of metastatic lymph nodes/
number of totally resected lymph nodes) 9 100 %
L lepidic, A acinar, P papillary, M micropapillary, S solid, IMA
invasive mucinous adenocarcinoma
a Percentage of patients with subtype of interest not observed or less
than 5 %
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0.484–0.982) (Table 4). No significant difference was
observed between other minor components and patient
survival.
DISCUSSION
Lymph node metastasis is a major way for cancer cells
to migrate from the primary tumor to distant organs, which
promises a poor prognosis for lung cancer patients. With
the classification of subtyping lung adenocarcinoma by the
IASLC/ATS/ERS,6 several studies have reported that
micropapillary- and solid-predominant subtypes were
related to poor prognoses;9,12–14,19–21 however, lung ade-
nocarcinomas usually contain a mixture of different
subtypes. Thus, it is necessary for clinicians and
researchers to understand whether minor components
influence patients’ prognoses to help predict their prog-
noses and make therapeutic strategies. Yeh et al. pointed
out that the presence of micropapillary or solid patterns
were of predictive value with increased risk of occult
lymph node metastasis;22 however, studies focusing on
minor components are limited. In this study, our aim was to
determine whether there was a correlation between minor
components of lung adenocarcinoma and lymph node
metastasis. According to our study of 1244 patients with
pathologically proven lung adenocarcinoma that was ini-
tially diagnosed between August 2006 and May 2013, we
found that patients with lung adenocarcinoma of lepidic
Micropapillary pattern in all patients (n = 956)
Micropapillary pattern in all patients (n = 956)
Solid pattern in all patients (n = 956)
Solid pattern in all patients (n = 956)
Negative (n = 859)
Minor component (n = 78)
Negative - censored
Minor component - censored
Minor component versus nagative p < 0.001
Predominant versus nagative p = 0.007
Minor component versus nagative p < 0.001
Predominant versus nagative p = 0.006
Minor component versus nagative p < 0.001
Predominant versus nagative p < 0.001
Minor component versus nagative p < 0.001
Predominant versus nagative p < 0.001
Predominant (n = 19)
Predominant - censored
Negative (n = 859)
Minor component (n = 78)
Negative - censored
Minor component - censored
Predominant (n = 19)
Predominant - censored
Negative (n = 671)
Minor component (n = 124)
Negative - censored
Minor component - censored
Predominant (n = 161)
Predominant - censored
Negative (n = 671)
Minor component (n = 124)
Negative - censored
Minor component - censored
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FIG. 1 Kaplan–Meier survival curves of RFS and OS for patients
with micropapillary and solid subtypes. a RFS for patients with
micropapillary-predominant tumors and tumors containing minor
micropapillary components; b RFS for patients with solid-predom-
inant tumors and tumors containing minor solid components; c OS for
patients with micropapillary-predominant tumors and tumors
containing minor micropapillary components; d OS for patients with
solid-predominant tumors and tumors containing minor solid com-
ponents. A two-tailed p\ 0.05 was regarded as statistically different.
Negative refers to the percentage of patients with subtype of interest
not observed or\ 5 %. RFS recurrence-free survival, OS overall
survival
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(p\ 0.001) subtype tended to have a lower rate of lymph
node metastasis, while patients with lung adenocarcinoma
of papillary, micropapillary and solid subtypes were more
likely to have lymph node metastasis (Table 1). These
results are consistent with several previous studies19–21,23,24
but none reported the results of patients with lung adeno-
carcinoma of the papillary subtype. In addition, our data
showed that patients with lung adenocarcinoma predomi-
nated by different subtypes, as well as patients presenting
with different minor components, experience different
possibilities of presenting with lymph node metastasis.
To further understand the relationship between different
subtypes and lymph node metastasis, we recorded the
number of metastatic lymph node stations/lymph nodes and
resected lymph node stations/lymph nodes for each pre-
dominant subtype and minor component, and calculated the
metastatic rate. According to our study, tumors with lepidic
components had a lower rate of metastatic lymph node
stations and lymph nodes, while tumors with micropapil-
lary and solid components had a higher metastatic rate of
lymph node stations and lymph nodes. Similar conclusions
can also be made for patients with lepidic-, micropapillary-
and solid-predominant and second predominant tumors
(Tables 2, 3; electronic supplementary Tables 2, 3), with
only one exception—the correlation between micropapil-
lary second predominant subtype and metastatic rate of
lymph node station, probably due to the sample size. That
is to say, tumors containing minor components of
micropapillary and solid subtypes are aggressive enough
and have the potential for lymph node metastasis.
In univariate analysis, patients presenting with
micropapillary and solid subtypes had shorter RFS and OS
(Fig. 1). Interestingly, whether tumors contained a minor
or predominant component of micropapillary and solid
subtypes was not significantly different in RFS (p = 0.973
and p = 0.635, respectively, data not shown) or OS
(p = 0.692 and p = 0.291, respectively, data not shown).
This finding suggests that minor components of
micropapillary and solid subtypes are as valuable as
micropapillary- and solid-predominant subtypes in pre-
dicting patients’ prognosis. In multivariate analysis, minor
components of micropapillary and solid subtypes were both
independent predictive factors of a poor prognosis
(Table 4). These results support the fact that micropapillary
and solid subtypes are poor indicators for patients’ prog-
nosis, even if they are minor components of a specific
tumor.
CONCLUSIONS
Minor components, as well as predominant subtypes of
micropapillary and solid subtypes of lung adenocarcinoma,
are independent poor indicators of lymph node metastasis
and prognosis. Our study concentrates not only on the
predominant subtype but also on minor components of lung
adenocarcinoma. It is believed that more data are needed to
better clarify this issue, and we hope that minor compo-
nents of lung adenocarcinoma are taken into consideration
by clinicians when predicting patients’ prognosis and
designing comprehensive therapeutic strategies in order to
benefit more patients.
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Micropapillary 0.524 0.388–0.708 \0.001
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Lepidic 1.730 0.878–3.413 0.113
Acinar 1.122 0.754–1.669 0.571
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Micropapillary 0.585 0.385–0.890 0.012
Solid 0.690 0.484–0.982 0.039
Invasive mucinous carcinoma 0.870 0.519–1.456 0.594
Multivariate Cox model was adjusted for sex, age, smoking status,
lymphovascular invasion or no lymphovascular invasion, tumor
location, and nodal status (N0, N1, or N2). A two-tailed p\ 0.05 was
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